Table 2.
Case group, N individuals | Control group, N individuals | Frequency of effect allele (L) |
OR (95% CI) | P value | P value adjusted for APOE-ε4 effect | |
---|---|---|---|---|---|---|
Case group, % | Reference group, % | |||||
PDnD, 84 | NC, 86 | 13.7 | 10.5 | 1.15 (0.59–2.26) | .69 | .58 |
PDD, 102 | NC and PDnD, 170 | 20.1 | 12.1 | 1.69 (1.05–2.76) | .033 | .73 |
DLB, 179 | NC and PDnD, 170 | 32.1 | 12.1 | 3.61 (2.39–5.59) | 3.23 × 10−9 | .66 |
DLB, 179 | PDD, 102 | 32.1 | 20.1 | 2.15 (1.40–3.38) | 6.37 × 10−4 | .64 |
DLB+AD, 46 | NC and PDnD, 170 | 37.0 | 12.1 | 4.40 (2.42–7.99) | 1.15 × 10−6 | .40 |
PDD+AD, 15 | NC and PDnD, 170 | 16.7 | 12.1 | 1.38 (0.44–3.57) | .53 | .17 |
DLB-AD, 47 | NC and PDnD, 170 | 20.2 | 12.1 | 1.71 (0.96–3.03) | .067 | .51 |
PDD-AD, 49 | NC and PDnD, 170 | 18.4 | 12.1 | 1.46 (0.78–2.64) | .22 | .63 |
NOTE. The results are reported as odds ratios (ORs) with their 95% confidence intervals (CIs). Model tested: TOMM40-L allele log-additive effect on risk compared with combined effect of other alleles, adjusted for age at death and sex. We also adjusted the same model for the additive effect of APOE-ε4 allele.
Results in bold are statistically significant after correction for multiple testing (P value < .0021).
Abbreviations: NC, normal controls; PDnD, Parkinson's disease without dementia; PDD+AD/PDD-AD, Parkinson's disease with dementia with/without neuropathologically defined Alzheimer's disease; DLB+AD/DLB-AD, dementia with Levy bodies with/without neuropathologically defined AD.